Archive » Medical Ultrasonography, March 2016, Volume 18, Number 1 » Original Papers » Subclinical myocardial impairment in SLE: insights from novel ultrasound techniques and clinical determinants.
(339 KB, PDF file)
Aims: Myocardial damage is frequent and often silent in systemic lupus erythematosus (SLE). The aim of the study was to determine the prevalence of myocardial damage by novel ultrasound techniques and to systematically assess the relationship between subclinical cardiac dysfunction and SLE-related clinical parameters. Material and methods: Seventy- ve consecu- tive SLE patients without evidence of cardiac disease and seventy-three controls underwent standard transthoracic echocar- diography using classical and novel ultrasound techniques: tissue Doppler imaging and speckle tracking echocardiography. Patient characteristics, cumulative organ damage and laboratory data were retrieved by medical chart review. Results: Within the cohort, 89.3% of the patients were female; mean±SD age and median (IQR) disease duration were 43.2±12.5 years and 8.03(6.3) years, respectively. SLE patients exhibited a signi cant decrement in endocardial longitudinal strain (-18.4% vs 19.3%, p=0.001) compared with controls. Diastolic dysfunction was detected in 34 (45.3%) of SLE patients. Major determi- nants of systolic and diastolic dysfunction were hypertension (p=0.023 and p<0.001, respectively), associated antiphospho- lipid syndrome (APS) (p<0.001 and p<0.001, respectively), cumulative damage accrual (p<0.001 and p=0.003, respectively), and disease duration (p=0.03 and p<0.001, respectively). Notably, anti-Ro antibodies were present in 37% of the SLE patients who had better systolic longitudinal performance. Neither disease activity, nor speci c organ involvement, were associated with myocardial impairment. Conclusion: Systolic longitudinal and diastolic performance impairments are frequent ndings in SLE patients without overt cardiovascular disease. Cumulative organ damage, disease duration, APS, and hypertension are major determinants for early heart involvement in SLE patients.